Does UPADACITINIB Cause Neoplasm malignant? 494 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 494 reports of Neoplasm malignant have been filed in association with UPADACITINIB (Rinvoq). This represents 0.8% of all adverse event reports for UPADACITINIB.
494
Reports of Neoplasm malignant with UPADACITINIB
0.8%
of all UPADACITINIB reports
22
Deaths
46
Hospitalizations
How Dangerous Is Neoplasm malignant From UPADACITINIB?
Of the 494 reports, 22 (4.5%) resulted in death, 46 (9.3%) required hospitalization, and 2 (0.4%) were considered life-threatening.
Is Neoplasm malignant Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for UPADACITINIB. However, 494 reports have been filed with the FAERS database.
What Other Side Effects Does UPADACITINIB Cause?
Pain (4,444)
Arthralgia (3,815)
Drug ineffective (3,384)
Covid-19 (2,978)
Rheumatoid arthritis (2,730)
Pain in extremity (2,353)
Fatigue (2,153)
Fall (2,081)
Surgery (2,037)
Therapy interrupted (1,741)
What Other Drugs Cause Neoplasm malignant?
RANITIDINE (10,648)
ADALIMUMAB (2,028)
APIXABAN (1,772)
ETANERCEPT (1,616)
METHOTREXATE (1,041)
TOFACITINIB (1,020)
RITUXIMAB (929)
INFLIXIMAB (892)
ABATACEPT (727)
RISANKIZUMAB-RZAA (715)
Which UPADACITINIB Alternatives Have Lower Neoplasm malignant Risk?
UPADACITINIB vs URAPIDIL
UPADACITINIB vs UREA
UPADACITINIB vs URIDINE TRIACETATE
UPADACITINIB vs UROFOLLITROPIN
UPADACITINIB vs URSODIOL